The Vanguard Group 13D and 13G filings for Akebia Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-13 4:58 pm Sale |
2023-12-29 | 13G | Akebia Therapeutics, Inc. AKBA |
The Vanguard Group | 7,607,472 4.040% |
-3,631,398 (-32.31%) |
Filing |
| 2023-02-09 10:54 am Sale |
2022-12-30 | 13G | Akebia Therapeutics, Inc. AKBA |
The Vanguard Group | 11,238,870 6.110% |
-7,120,550 (-38.78%) |
Filing |
| 2022-06-09 2:15 pm Purchase |
2022-05-31 | 13G | Akebia Therapeutics, Inc. AKBA |
The Vanguard Group | 18,359,420 10.000% |
5,123,751 (+38.71%) |
Filing |
| 2022-02-09 3:16 pm Purchase |
2021-12-31 | 13G | Akebia Therapeutics, Inc. AKBA |
The Vanguard Group | 13,235,669 7.560% |
4,800,910 (+56.92%) |
Filing |
| 2021-02-10 10:30 am Purchase |
2020-12-31 | 13G | Akebia Therapeutics, Inc. AKBA |
The Vanguard Group | 8,434,759 5.840% |
8,434,759 (New Position) |
Filing |